Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a Medicaid population: Clinical and economic evaluation

P and T

Volumn 38, Issue 2, 2013, Pages 109-115

  Ward, Alex ^a   Quon, Peter ^a   Abouzaid, Safiya ^b   Haber, Noah ^a   Ahmed, Saeed ^b   Kim, Edward ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cardiometabolic; Medicaid; Schizophrenia; Second generation antipsychotic agents

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK FACTOR; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 84874132424     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66(9):1122-1129.
2. Croghan TW, Johnstone BM, Buesching DP, Kessler RC. Information needs for medication coverage decisions in a state Medicaid program. Med Care 1999;37(4 Suppl):AS24-AS31.
3. U.S. Department of Health and Human Services. Schizophrenia. 2006. Available at: www.nimh.nih.gov/health/publications/index. shtml. Accessed November 1, 2011.
4. U.S. Public Health Service. Office of the Surgeon General. Mental Health. A Report of the Surgeon General. 1999. Available at: http:// profiles.nlm.nih.gov/ps/retrieve/ResourceMetadata/nnbbhs. Accessed November 1, 2011.
5. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161(9):1709-1711.
6. Bell RC, Farmer S, Ries R, Srebnik D. Metabolic risk factors among Medicaid outpatients with schizophrenia receiving secondgeneration antipsychotics. Psychiatric Serv 2009;60(12):1686-1689.
7. Kabinoff GS, Toalson PA, Healey KM, et al Metabolic issues with atypical antipsychotics in primary care: Dispelling the myths. Prim Care Companion J Clin Psychiatry 2003;5(1):6-14.
8. Schmidt MI, Duncan BB, Bang H, et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005;28(8):2013-2018.
9. Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008;118(2):124-130.
10. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Res 2005;80(1):45-53.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
12. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139(2 Part 1):272-281.
13. Agency for Healthcare Research and Quality (AHRQ). Statistics on Hospital Stays. Nationwide Inpatient Sample. 2008. Available at: http://hcupnet.ahrq.gov. Accessed November 3, 2011.
14. Angina pectoris. 2011. Available at: www.emedicinehealth.com/ angina_pectoris/page8_em.htm. Accessed April 1, 2011.
15. Coronary Artery Disease. 2011. Available at: www.emedicinehealth. com/coronary_artery_disease-health/page13_em.htm. Accessed April 1, 2011.
16. Agency for Health Care Administration. Florida Medicaid, Summary of Services, Fiscal Year 10/11. 2011. Available at: www.ahca.myflorida. com/Medicaid/flmedicaid.shtml. Accessed April 1, 2011.
17. Agency for Healthcare Research and Quality (AHRQ). Medical Panel Expenditure Survey. 2011. Available at: http://meps.ahrq. gov/mepsweb. Accessed April 4, 2011.
18. Consumer Price Index (CPI). Series cuur0000sam. 2011. Available at: www.bls.gov/cpi. Accessed April 1, 2011.
19. Red Book. Montvale, N.J.: PDR Network, LLC.; 2011. Available at: www.pdr.net. Accessed January 2, 2013.
20. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67(1):17-24.
21. Barnett AH, Millar HL, Loze JY, et al. UK cost-consequence analysis of aripiprazole in schizophrenia: Diabetes and coronary heart disease risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci 2009;259(4):239-247.
22. Neubauer AS, Deuschle M, Marschall D, et al. Cost-consequence of diabetes and coronary heart disease in patients with schizophrenia in Germany: A social and health insurance perspective. Gesundheitsokonomie Qualitatsmanage 2009;14(2):95-103.
23. Del Valle MC, Loebel AD, Murray S, et al. Change in Framingham risk score in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine. Prim Care Companion J Clin Psychiatry 2006;8(6):329-333.
24. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105(1-3):175-187.
25. Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, 1-year trial. Value Health 2006;9(2):77-89.
26. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163(12):2080-2089.
27. Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: Results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007;191:14-22.
28. Ascher-Svanum H, Stensland MD, Peng X, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin 2011;27(1):115-122.
29. McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine, and risperidone in Canada: A cost-effectiveness analysis. J Eval Clin Pract 2010;16(4):744-755.
30. Zyprexa (olanzapine), package insert/full prescribing information. Indianapolis: Eli Lilly; revised June 2, 2011. Available at: http:// pi.lilly.com/us/zyprexa-pi.pdf. Accessed January 2, 2013.
31. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89(1-3):91-100.
32. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007;58(7):1007-1010.
33. Misawa F, Shimizu K, Fujii Y, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study. BMC Psychiatry 2011;11:118.
34. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24(6):412-424.
35. De Hert M, Falissard B, Mauri M, et al. Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR study. European Neuropsychopharmacol 2008;18(S4):S444-S445.
36. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 2009;8(1):15-22.
37. Jacob R, Chowdhury AN. Metabolic comorbidity in schizophrenia. Indian J Med Sci 2008;62(1):23-31.
38. Kannabiran M, Singh V. Metabolic syndrome and atypical antipsychotics: A selective literature review. German J Psychiatry 2008;11(3):111-122.
39. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80(1):19-32.
40. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Res 2008;101(1-3):273-286.
41. Nulkar A, Watkinson HMO, Waton A, Mackin P. Cardio-metabolic risk profiles of community psychiatric patients in North Tyneside, United Kingdom. J Cancer Educ 2009;24:S535.
42. Usher K, Foster K, Park T. The metabolic syndrome and schizophrenia: The latest evidence and nursing guidelines for management. J Psychiatric Mental Health Nurs 2006;13(6):730-734.
43. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69(3):472-479.